Gilead Reports Results of Biktarvy for the Treatment of HIV-1 in Adults (Treatment Naive)

 Gilead Reports Results of Biktarvy for the Treatment of HIV-1 in Adults (Treatment Naive)

Gilead and Galapagos’ Report Results of Filgotinib in P-III FINCH 3 Trial for Moderate-To-Severe Active Rheumatoid Arthritis (RA)

 Shots:

  • The P-III 1489 study has assessed Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets) in ratio (1:1) to treat HIV-1 infection in adults for 96 weeks, testing safety and efficacy
  • P-III 1489 study results ((abacavir/dolutegravir/lamivudine (600/50/300mg, ABC/DTG/3TC) or Biktarvy): meGFR @96wks. (-7.8 mL/min vs. -9.6 mL/min); mean percent changes from baseline in spine and hip bone mineral density (spine: -0.71 vs. -0.22) (hip: -1.13 vs. -1.26); was well tolerated
  • Bictegravir is a fixed dose drug containing 50 mg bictegravir, 200 mg emtricitabine, and 25 mg tenofovir alafenamide currently evaluated for the treatment naïve HIV-1 infection in adults

Click here to read full press release/ article | Ref: Gilead | Image: Seeking Alpha

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post